Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
UPDATE: DXC Technology (DXC) PT Raised to $97 at Cantor Fitzgerald
-
Luxoft Holding (LXFT) PT Raised to $54 at Cantor Fitzgerald
-
PayPal (PYPL) PT Raised to $93 at Cantor Fitzgerald
-
Evofem Biosciences Announces Closing of Public Offering of Common Stock and Warrants
-
Elliott Management Releases Letter to Board of athenahealth (ATHN) Following $160/Share Proposal, Calls For Sale Process
-
Elliott Management Releases Letter to the Board of athenahealth
-
Melinta Therapeutics (MLNT) Prices 22M Share Common Offering at $5/Sh
-
Melinta Therapeutics Announces Pricing of Public Offering of Common Stock
-
Melinta Therapeutics Announces Pricing of Public Offering of Common Stock
-
UPDATE: Cantor Fitzgerald Starts Apellis Pharmaceuticals (APLS) at Overweight
-
Verastem Oncology Announces Closing of Underwriter’s Option to Purchase Additional Shares
-
Spero Therapeutics (SPRO) Data Underscores Platform is Underappreciated - Cantor Fitzgerald
-
Exponent (EXPO) PT Raised to $105 at Cantor Fitzgerald
-
Cantor Fitzgerald Remains Bullish on Aetna (AET)
-
Cantor Fitzgerald Maintains Bullish View on Spark Therapeutics (ONCE) Following SPK-9001 Update
-
Bonds steady before two-year note sale
-
Evofem Biosciences (EVFM) Prices 8.5M Shares Common Offering at $4.69/Sh
-
Evofem Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
-
ProPhotonix Announces that its Laser Facility has Achieved ISO9001: 2015
-
Melinta Therapeutics (MLNT) to Offer $75M in Common Stock
-
Melinta Therapeutics Announces Proposed Offering of Common Stock
-
Melinta Therapeutics Announces Proposed Offering of Common Stock
-
Cantor Fitzgerald Maintains OW, $16 PT on Nabriva (NBRV) Following Phase 3 Data For Oral Lefamulin
-
Cidara Therapeutics (CDTX) Announces Offering of Common Stock, Warrants
-
Cidara Therapeutics Announces Offering of Common Stock and Warrants
-
ProPhotonix Limited - STKR - ProPhotonix Announces AGM Results
-
eHealth (EHTH) PT Raised to $22 at Cantor Fitzgerald; 'Fundamentals Should Improve in 2H18 and Beyond'
-
Orchid Island Capital Announces May 2018 Monthly Dividend and April 30, 2018 RMBS Portfolio Characteristics
-
Verastem Inc. (VSTM) Prices 7.78M Share Common Offerings at $4.50/Sh
-
Verastem Oncology Announces Pricing of Public Offering of Common Stock
-
Five Star Quality Care (FVE) PT Lowered to $3 at Cantor Fitzgerald
-
Verastem (VSTM) Commences $35M Common Stock Offering
-
Verastem Oncology Announces Public Offering of Common Stock
-
ProPhotonix Expands Red Laser Diodes with 638nm - STKR - ProPhotonix Limited
-
Cantor Asks if Athenahealth (ATHN) Efforts to Drive Growth is as Valuable as Elliott Offer
-
The Currency of Tomorrow is Here - Makor Group Launches a New Crypto Brokerage Firm: Enigma Securities
-
Aetna (AET) Trump Proposal Unlikely To Impact Managed Care - Cantor Fitzgerald
-
Synergy Pharmaceuticals (SGYP) PT Lowered to $6 at Cantor Fitzgerald
-
Celsion Corporation Reports First Quarter 2018 Financial Results and Provides Business Update
-
CareTrust REIT (CTRE) PT Raised to $17 at Cantor Fitzgerald
-
Supernus Pharmaceuticals (SUPN) PT Raised to $55 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1Q
-
Cantor Fitzgerald Remains Bullish on Mallinckrodt (MNK) Following 1Q
-
7 Key Points In Valeant Pharma's (VRX) Turnaround - Cantor Fitzgerald
-
Gartner (IT) PT Raised to $148 at Cantor Fitzgerald
-
Cantor Fitzgerald Upgrades Arrowhead Research (ARWR) to Overweight
-
Cerus (CERS) PT Raised to $7 at Cantor Fitzgerald
-
CytoSorbents Reports Strong First Quarter 2018 Financial Results
-
Valeant Pharmaceuticals (VRX): 'A Turnaround For The Ages' - Cantor Fitzgerald
-
Cantor Fitzgerald Downgrades Egalet Ltd (EGLT) to Neutral

